Lactobacillus helveticus Lafti L10 Supplementation Modulates Mucosal and Humoral Immunity in Elite Athletes: A Randomized, Double-Blind, Placebo-Controlled Trial

ABSTRACTMichalickova, DM, Kostic-Vucicevic, MM, Vukasinovic-Vesic, MD, Stojmenovic, TB, Dikic, NV, Andjelkovic, MS, Djordjevic, BI, Tanaskovic, BP, and Minic, RD. Lactobacillus helveticus Lafti L10 supplementation modulates mucosal and humoral immunity in elite athletesa randomized, double-blind, pl...

Full description

Saved in:

Bibliographic Details
Published in:	Journal of strength and conditioning research Vol. 31; no. 1; pp. 62 - 70
Main Authors:	Michalickova, Danica M, Kostic-Vucicevic, Marija M, Vukasinovic-Vesic, Milica Dj, Stojmenovic, Tamara B, Dikic, Nenad V, Andjelkovic, Marija S, Djordjevic, Brizita I, Tanaskovic, Bojana P, Minic, Rajna D
Format:	Journal Article
Language:	English
Published:	United States Copyright by the National Strength & Conditioning Association 01-01-2017 Lippincott Williams & Wilkins Ovid Technologies
Subjects:	Adult Antibodies, Bacterial - immunology Athletes Bacteria Clinical trials Double-Blind Method Female Humans Immunity (Disease) Immunity, Humoral - immunology Immunity, Mucosal - physiology Immunoglobulin A - immunology Immunoglobulin G - immunology Immunoglobulin M - immunology Immunoglobulins Lactobacillus helveticus Lactobacillus helveticus - immunology Lactobacillus rhamnosus Male Oxygen Consumption Probiotics Probiotics - pharmacology Saliva - immunology Young Adult
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Description
Summary:	ABSTRACTMichalickova, DM, Kostic-Vucicevic, MM, Vukasinovic-Vesic, MD, Stojmenovic, TB, Dikic, NV, Andjelkovic, MS, Djordjevic, BI, Tanaskovic, BP, and Minic, RD. Lactobacillus helveticus Lafti L10 supplementation modulates mucosal and humoral immunity in elite athletesa randomized, double-blind, placebo-controlled trial. J Strength Cond Res 31(1)62–70, 2017—To test the influence of probiotic supplementation on humoral immune response, a double-blind, placebo-controlled trial was conducted. Thirty athletes (24 males and 6 females, femalesV[Combining Dot Above]O2max 38.2 ± 4.9 ml·kg·min, age 23.2 ± 1.4 years; malesV[Combining Dot Above]O2max 57.5 ± 9.2 ml·kg·min, age 24.0 ± 2.4 years, mean ± SD) were randomized either to the probiotic group (Lactobacillus helveticus Lafti L10, 2 × 10 colony-forming units) or to the placebo group. Serum and saliva samples were collected at the baseline and after 14 weeks. Total and specific antibacterial antibody levels of IgM, IgG, and IgA classes were determined for different bacteria in the serum, and in saliva, total and specific antibacterial IgA levels were examined. Total IgM was elevated in both probiotic (18%, 15–20%; mean, 90% confidence interval; p = 0.02) and placebo group (35%, 22–47%; p = 0.02), without observed differences in changes between the groups. No significant changes in IgM levels specific for tested bacteria were found. Total IgG level was constant in both groups. A significant (16%, −2.8 to 35%, p = 0.04) reduction of anti–Enterococcus faecalis IgG was noted in the placebo group, in comparison with the probiotic group. There was a substantial decrease in total IgA level in the placebo group, when measured either in serum (15%, 12–18%, p = 0.04) or in saliva (35%, −1.4 to 53%, p = 0.03). Significantly reduced levels of serum anti–lactic acid bacteria IgA antibodies in the placebo group compared with the probiotic group were detected for Lactobacillus rhamnosus LA68 (24%, 5.8–42%, p = 0.02) and for L. rhamnosus LB64 (15%, 2.7–27%, p = 0.02). Probiotic administration could have beneficial effects on systemic humoral and mucosal immune responses.
Bibliography:	ObjectType-Article-2 SourceType-Scholarly Journals-1 ObjectType-News-1 ObjectType-Feature-3 content type line 23 ObjectType-Article-1 ObjectType-Feature-2
ISSN:	1064-8011 1533-4287
DOI:	10.1519/JSC.0000000000001456